15 Stocks That Will Go to The Moon According to Analysts

1. Vaxcyte, Inc. (NASDAQ:PCVX)

Average Upside Potential: 91.87%

Number of Hedge Fund Holders: 50

Vaxcyte, Inc. (NASDAQ:PCVX) is a clinical-stage vaccine innovation company engineering high-fidelity vaccines. The firm continues to engage in developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.  Through advanced chemistry and modern synthetic techniques, the company re-engineers how highly complex vaccines are created.

Alongside a potential best-in-class pneumococcal conjugate vaccine (PCV) franchise, the company’s lead clinical candidate is VAX-24, a 24-valent pneumococcal conjugate vaccine (PCV) that is to prevent invasive pneumococcal disease. It has the potential to be a best-in-class PCV in a $7 billion global market that will be growing massively and is expected to reach nearly $13 billion by 2027. The vaccine has received FDA Breakthrough Therapy designation for the prevention of invasive pneumococcal disease in adults.

Vaxcyte, Inc. (NASDAQ:PCVX) is currently advancing to the second stage of the ongoing phase 2 study evaluating VAX-31 for the prevention of invasive pneumococcal disease in infants. The 31-valent pneumococcal conjugate vaccine (PCV) candidate is made to prevent invasive pneumococcal disease which is especially serious in infants, older adults, young children,  and those having immune deficiencies or certain chronic health conditions.

While we acknowledge the potential of PCVX as an investment, our conviction lies in the belief that some deeply undervalued AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for a deeply undervalued AI stock that is more promising than PCVX but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.